Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; 28 of the 31 sources its claims cite were checked for support.

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Open access
Milà-Alomà, Marta, Ashton, Nicholas J., Shekari, Mahnaz, Salvadó, Gemma, Ortiz-Romero, Paula, Montoliu-Gaya, Laia, Benedet, Andrea L., Karikari, Thomas K., Lantero-Rodriguez, Juan, Vanmechelen, Eugeen, Day, Theresa A., González-Escalante, Armand, Sánchez-Benavides, Gonzalo, Minguillon, Carolina, Fauria, Karine, Molinuevo, José Luis, Dage, Jeffrey L., Zetterberg, Henrik, Gispert, Juan Domingo, Suárez-Calvet, Marc, Blennow, Kaj · 2022 · Nature Medicine

Abstract

Blood biomarkers indicating elevated amyloid-β (Aβ) pathology in preclinical Alzheimer’s disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient Aβ pathology, but a comprehensive comparison with other putative blood biomarkers is lacking. In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40) were significantly changed in preclinical Alzheimer’s disease. However, plasma p-tau231 reached abnormal levels with the lowest Aβ burden. Plasma p-tau231 and p-tau217 had the strongest association with Aβ positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in Aβ PET uptake in individuals without overt Aβ pathology at baseline. In summary, plasma p-tau231 and p-tau217 better capture the earliest cerebral Aβ changes, before overt Aβ plaque pathology is present, and are promising blood biomarkers to enrich a preclinical population for Alzheimer’s disease clinical trials.

Overview

CoChat Summary

TL;DR

In the ALFA+ cohort, plasma p-tau231 and p-tau217 best captured the earliest amyloid-β changes in preclinical Alzheimer’s disease, with p-tau231 becoming abnormal at the lowest Aβ PET burden. These biomarkers may help enrich preclinical trial populations, though platform and cohort limitations remain.

Key findings

  • All tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL, Aβ42/40) were significantly changed in preclinical AD, but plasma p-tau231 reached abnormal levels earliest, at 26.4 Centiloids, followed by p-tau217 at 35.4 Centiloids and GFAP at 65.5 Centiloids; p-tau181, NfL and Aβ42/40 did not reach the two z-score abnormality threshold.
  • Plasma p-tau231 and p-tau217 had the strongest associations with Aβ PET retention in early-accumulating regions, including orbitofrontal areas, anterior and posterior cingulate gyri, insula and precuneus.
  • In participants without established Aβ pathology at baseline (Aβ PET <30 Centiloids), only plasma p-tau231 and p-tau217 were significantly associated with longitudinal Aβ PET Centiloid increases at follow-up (P = 0.041 for both).
  • For discriminating Aβ status by CSF Aβ42/40, the highest AUCs were plasma Aβ42/40 (AUC = 0.750, 95% CI = 0.702–0.798) and p-tau231 (AUC = 0.740, 95% CI = 0.688–0.793); combined with age, sex and APOE ε4, p-tau231 reached AUC = 0.810 (95% CI = 0.766–0.854), Aβ42/40 AUC = 0.798 (95% CI = 0.754–0.843) and p-tau217 AUC = 0.797 (95% CI = 0.751–0.842).

Methods

  • Design and sample: ALFA+ cohort study of 397 cognitively unimpaired middle-aged individuals (61.1 ± 4.67 years), including 135 (34.0%) Aβ-positive by CSF Aβ42/40; 339 had baseline Aβ PET, and subsets had 3-year longitudinal cognitive (n = 214) and Aβ PET (n = 145) data.
  • Biomarkers and imaging: plasma p-tau181, p-tau217, p-tau231, GFAP, NfL and Aβ42/40; CSF Aβ42/40 and M-p-tau181; [18F]flutemetamol Aβ PET quantified in Centiloids with early (≥12) and later (≥30) cut-offs.
  • Analysis: ANCOVA and Cohen’s d for group differences; robust local weighted regression for biomarker trajectories; voxel-wise linear regression for Aβ PET associations; ROC/AUC with DeLong’s test; linear regression for longitudinal cognitive and Aβ PET change.

Limitations

  • Stated in the paper: different platforms were used to measure plasma biomarkers, and the contribution of assay platform to diagnostic accuracy remains unclear.
  • Stated in the paper: ALFA+ includes participants with higher AD risk by design (high APOE ε4 carriership and Aβ positivity) and does not represent normal aging in the general population.
  • Evident from the text: the main biomarker comparisons are cross-sectional, and longitudinal analyses rely on smaller subsets (n = 214 for cognition; n = 145 for Aβ PET), with no external independent validation cohort reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01925-w

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Plasma biomarkers and Aβ pathology. a,b, Effect sizes of plasma biomarker levels change by AT groups (a; n = 397; n = 249 A−T−, n = 104 A+T−, n = 31 A+T+, n = 13 A−T+) and by CSF/PET groups (b; n = 339; n = 224 CSF/PET Aβ negative, n = 89 low burden, n = 26 CSF/PET Aβ positive). Individuals with a low burden of Aβ pathology were defined as CSF Aβ42/40 <0.071 and Aβ PET <30 Centiloids. The effect size of group differences was estimated by calculating Cohen’s d, in which the dependent variable was the residual of log(transformed) plasma biomarkers regressed on age and sex. The error bars denote the 95% CIs. c,d, The graphs represent the z-score changes of each plasma biomarker using the mean and the s.d. of that plasma biomarker in the group of participants with CSF Aβ42/40 >0.1 as a reference. The resulting z-scores are shown as a function of Aβ PET Centiloids (c) or CSF Aβ42/40 (d) using a robust local weighted regression method. The vertical dashed lines depict the Aβ PET 12 Centiloids (c) and CSF Aβ42/40 positivity cut-off (d). The horizontal dashed lines depict the abnormality threshold held at 1.5 and 2 s.d. above the mean. The horizontal axis direction of CSF Aβ42/40 (d) was inverted. e, Association of plasma biomarkers with Aβ PET at the voxel level. Associations were tested using voxel-wise, univariate, independent, linear regression models with age and sex as covariates. All plasma biomarkers showed a significant association with Aβ deposition in orbitofrontal and precuneus. These associations were stronger with plasma p-tau231 and p-tau217 and also extended to the insula and striatum. Statistical significance was set at P < 0.001 uncorrected for multiple comparisons with a cluster size of k > 100 voxels. All tests were one sided but contrasts in both directions were tested. No significant associations were found in the opposite direction. Statistical maps were resliced to 0.5 mm3 (cubic) for visualization purposes.
Fig. 1 Plasma biomarkers and Aβ pathology. a,b, Effect sizes of plasma biomarker levels change by AT groups (a; n = 397; n = 249 A−T−, n = 104 A+T−, n = 31 A+T+, n = 13 A−T+) and by CSF/PET groups (b; n = 339; n = 224 CSF/PET Aβ negative, n = 89 low burden, n = 26 CSF/PET Aβ positive). Individuals with a low burden of Aβ pathology were defined as CSF Aβ42/40 <0.071 and Aβ PET <30 Centiloids. The effect size of group differences was estimated by calculating Cohen’s d, in which the dependent variable was the residual of log(transformed) plasma biomarkers regressed on age and sex. The error bars denote the 95% CIs. c,d, The graphs represent the z-score changes of each plasma biomarker using the mean and the s.d. of that plasma biomarker in the group of participants with CSF Aβ42/40 >0.1 as a reference. The resulting z-scores are shown as a function of Aβ PET Centiloids (c) or CSF Aβ42/40 (d) using a robust local weighted regression method. The vertical dashed lines depict the Aβ PET 12 Centiloids (c) and CSF Aβ42/40 positivity cut-off (d). The horizontal dashed lines depict the abnormality threshold held at 1.5 and 2 s.d. above the mean. The horizontal axis direction of CSF Aβ42/40 (d) was inverted. e, Association of plasma biomarkers with Aβ PET at the voxel level. Associations were tested using voxel-wise, univariate, independent, linear regression models with age and sex as covariates. All plasma biomarkers showed a significant association with Aβ deposition in orbitofrontal and precuneus. These associations were stronger with plasma p-tau231 and p-tau217 and also extended to the insula and striatum. Statistical significance was set at P < 0.001 uncorrected for multiple comparisons with a cluster size of k > 100 voxels. All tests were one sided but contrasts in both directions were tested. No significant associations were found in the opposite direction. Statistical maps were resliced to 0.5 mm3 (cubic) for visualization purposes.CC BY · PubMed Central
Extended Data Fig. 1 Plasma biomarkers by CSF/PET Aβ groups. Violin plots comparing plasma biomarkers between CSF/PET Aβ groups (n = 339; n = 224 CSF/PET Aβ-negative, n = 89 Low burden, n = 26 CSF/PET Aβ-positive). Individuals with a low burden of Aβ pathology were defined as CSF Aβ42/40 < 0.071 and Aβ PET Centiloid < 30. The box plots depict the median (horizontal bar), interquartile range (IQR, hinges), and 1.5 × IQR (whiskers). Group comparisons were computed with a one-way ANCOVA adjusting for age and sex, followed by Tukey-corrected post hoc pairwise comparisons. The percentage (%) of change in mean levels of plasma biomarkers in the low burden group compared to the CSF/PET Aβ-negative group is shown.
Extended Data Fig. 1 Plasma biomarkers by CSF/PET Aβ groups. Violin plots comparing plasma biomarkers between CSF/PET Aβ groups (n = 339; n = 224 CSF/PET Aβ-negative, n = 89 Low burden, n = 26 CSF/PET Aβ-positive). Individuals with a low burden of Aβ pathology were defined as CSF Aβ42/40 < 0.071 and Aβ PET Centiloid < 30. The box plots depict the median (horizontal bar), interquartile range (IQR, hinges), and 1.5 × IQR (whiskers). Group comparisons were computed with a one-way ANCOVA adjusting for age and sex, followed by Tukey-corrected post hoc pairwise comparisons. The percentage (%) of change in mean levels of plasma biomarkers in the low burden group compared to the CSF/PET Aβ-negative group is shown.CC BY · PubMed Central
Extended Data Fig. 2 ROC curves for the discrimination of Aβ PET Centiloid 12 or 30. ROC analysis was performed to test the accuracy of plasma biomarkers (A), and plasma biomarkers in combination with a base risk factors model (age, sex and APOE ε4 status) (B), to discriminate participants with Aβ PET Centiloid ≥ 12 from those with Aβ PET Centiloid < 12. The same analyses were performed on both plasma biomarkers alone (C) or in combination with a base risk factors model (D) to discriminate participants with Aβ PET Centiloid ≥ 30 from those with Aβ PET Centiloid < 30.
Extended Data Fig. 2 ROC curves for the discrimination of Aβ PET Centiloid 12 or 30. ROC analysis was performed to test the accuracy of plasma biomarkers (A), and plasma biomarkers in combination with a base risk factors model (age, sex and APOE ε4 status) (B), to discriminate participants with Aβ PET Centiloid ≥ 12 from those with Aβ PET Centiloid < 12. The same analyses were performed on both plasma biomarkers alone (C) or in combination with a base risk factors model (D) to discriminate participants with Aβ PET Centiloid ≥ 30 from those with Aβ PET Centiloid < 30.CC BY · PubMed Central
Extended Data Fig. 3 ROC curves for the discrimination of Aβ status (CSF Aβ42/40). ROC analysis was performed to test the accuracy of plasma biomarkers (A), and plasma biomarkers in combination with a base risk factors model (age, sex and APOE ε4 status) (B), to discriminate between Aβ status as defined by CSF Aβ42/40.
Extended Data Fig. 3 ROC curves for the discrimination of Aβ status (CSF Aβ42/40). ROC analysis was performed to test the accuracy of plasma biomarkers (A), and plasma biomarkers in combination with a base risk factors model (age, sex and APOE ε4 status) (B), to discriminate between Aβ status as defined by CSF Aβ42/40.CC BY · PubMed Central
Extended Data Fig. 4 Association of plasma biomarkers with longitudinal change in cognition by Aβ status (CSF Aβ42/40). Scatter plots representing the associations of each of the plasma biomarkers with annualized change in PACC scores. Each point depicts the value of the plasma biomarker of an individual and the solid lines indicate the regression line for each of the groups. The dashed line indicates the regression line of the whole sample. The error bands denote the 95% CIs. The standardized regression coefficients (β) and P values are shown and were computed using a linear regression with the annualized change in PACC scores as the dependent variable, adjusting by age, sex and years of education. All tests were two-sided. Annualized change in PACC scores was computed as the subtraction of PACC scores at visit 2 minus those at visit 1 divided by the time difference between the two visits in years. At the nominal level, there was a significant interaction between CSF Aβ status (as defined by CSF Aβ42/40) and plasma p-tau231. Thus, we performed a stratified analysis by CSF Aβ status for this biomarker, and we found a significant association of plasma p-tau231 with PACC score longitudinal changes in the CSF Aβ-positive group (β = –0.27, P = 0.023) but not in the Aβ-negative group (β = 0.054; P = 0.51). See Supplementary Table 8 for the detailed analyses, including FDR correction for multiple testing.
Extended Data Fig. 4 Association of plasma biomarkers with longitudinal change in cognition by Aβ status (CSF Aβ42/40). Scatter plots representing the associations of each of the plasma biomarkers with annualized change in PACC scores. Each point depicts the value of the plasma biomarker of an individual and the solid lines indicate the regression line for each of the groups. The dashed line indicates the regression line of the whole sample. The error bands denote the 95% CIs. The standardized regression coefficients (β) and P values are shown and were computed using a linear regression with the annualized change in PACC scores as the dependent variable, adjusting by age, sex and years of education. All tests were two-sided. Annualized change in PACC scores was computed as the subtraction of PACC scores at visit 2 minus those at visit 1 divided by the time difference between the two visits in years. At the nominal level, there was a significant interaction between CSF Aβ status (as defined by CSF Aβ42/40) and plasma p-tau231. Thus, we performed a stratified analysis by CSF Aβ status for this biomarker, and we found a significant association of plasma p-tau231 with PACC score longitudinal changes in the CSF Aβ-positive group (β = –0.27, P = 0.023) but not in the Aβ-negative group (β = 0.054; P = 0.51). See Supplementary Table 8 for the detailed analyses, including FDR correction for multiple testing.CC BY · PubMed Central
Extended Data Fig. 5 Association of plasma biomarkers with longitudinal change in Aβ deposition in individuals with Aβ PET Centiloids < 30. In order to assess whether plasma biomarkers are associated with longitudinal Aβ aggregation in the earliest stages of the Alzheimer’s continuum, we conducted a sensitivity analysis in those individuals with Aβ PET Centiloid < 30. Plasma p-tau231 and p-tau217 were significantly associated with Aβ PET Centiloid increases. Scatter plots represent the associations of each of the plasma biomarkers with annualized change in Aβ PET Centiloids in individuals with Aβ PET Centiloids < 30. Each point depicts the value of the plasma biomarker of an individual and the solid lines indicate the regression line. The error bands denote the 95% CIs. The standardized regression coefficients (β) and P values are shown and were computed using a linear regression with the annualized change in Aβ PET Centiloids as the dependent variable, adjusting by age and sex. All tests were two-sided. Annualized change in Aβ PET Centiloids was computed as the subtraction of Centiloid values at visit 2 minus those at visit 1 divided by the time difference between the two visits in years. See Supplementary Table 10 for the detailed analyses, including FDR correction for multiple testing.
Extended Data Fig. 5 Association of plasma biomarkers with longitudinal change in Aβ deposition in individuals with Aβ PET Centiloids < 30. In order to assess whether plasma biomarkers are associated with longitudinal Aβ aggregation in the earliest stages of the Alzheimer’s continuum, we conducted a sensitivity analysis in those individuals with Aβ PET Centiloid < 30. Plasma p-tau231 and p-tau217 were significantly associated with Aβ PET Centiloid increases. Scatter plots represent the associations of each of the plasma biomarkers with annualized change in Aβ PET Centiloids in individuals with Aβ PET Centiloids < 30. Each point depicts the value of the plasma biomarker of an individual and the solid lines indicate the regression line. The error bands denote the 95% CIs. The standardized regression coefficients (β) and P values are shown and were computed using a linear regression with the annualized change in Aβ PET Centiloids as the dependent variable, adjusting by age and sex. All tests were two-sided. Annualized change in Aβ PET Centiloids was computed as the subtraction of Centiloid values at visit 2 minus those at visit 1 divided by the time difference between the two visits in years. See Supplementary Table 10 for the detailed analyses, including FDR correction for multiple testing.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 0 Not valid · 1 Not checked · 37 Own results and interpretations

17 more claims

Create a free account to see all 51 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 20

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 33 references

Cited by

See all 353

Metadata

Authors
Milà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., Day, T. A., González-Escalante, A., Sánchez-Benavides, G., Minguillon, C., Fauria, K., Molinuevo, J. L., Dage, J. L., Zetterberg, H., Gispert, J. D., Suárez-Calvet, M., & Blennow, K.
Affiliations
  • King's College London (GB)
  • Universitat Pompeu Fabra (ES)
  • Instituto de Salud Carlos III (ES)
  • University of Pittsburgh (US)
  • ADx NeuroSciences (BE)
  • Eli Lilly (United States) (US)
  • Sahlgrenska University Hospital (SE)
Corresponding author
Blennow, Kaj
Venue
Nature Medicine
Published
2022-08-11
Volume
28
Issue
9
Pages
1797-1801
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4292865371
Cited by
353
References
33
Citations by year
2026: 47 · 2025: 105 · 2024: 122 · 2023: 69 · 2022: 10
FWCI
47.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by)
Funders
  • Alzheimer's Association (ADSF-21-831377-C, ZEN-21-848495, 21-831376 -C, ADSF‐21‐831376‐C, ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, #ADSF-21-831381-C, 100010434, 2021 Zenith Award, JPND2019-466-236, -21-831381-C, TriBEKa-17-519007, -21- 831377-C)
  • Alzheimer's Drug Discovery Foundation (2016862, FO2017-0243, 201809, ADSF-21-831381-C, 2017-00915, #ALFGBG-715986, ZEN-21-848495, 201809–2016862, ADSF-21-831377-C, 860197, JPND2019-466-236, 201809-2016615, #ADSF-21-831376-C, #RDAPB‐201809‐2016615, AF-742881)
  • Eli Lilly and Company
  • Familjen Erling-Perssons Stiftelse (#FO2017-0243, FO2019-0228, ALZ2022-0006, 860197)
  • Stiftelsen för Gamla Tjänarinnor (860197, FO2019‐0228, 2017-00915)
  • Agentschap Innoveren en Ondernemen (140105)
  • EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
  • European Federation of Pharmaceutical Industries and Associations (115952, RYC-2013-13054)
  • Ministerio de Ciencia, Innovación y Universidades (RTI2018‑102261, 100010434, RYC-2013-13054, RTI2018)
  • University College London
  • European Commission (100010434, 847648, 948677, 115952, HORIZON2020, ZEN-21-848495, JPND2019‐466‐236, 860197, ID 100010434)
  • ZonMw (733051102)
  • Fonds National de la Recherche Luxembourg
  • Bundesministerium für Bildung und Forschung
  • Ministerio de Economía y Competitividad (JPND2019-466-236, RYC‐2013‐13054, ZEN-21-848495, 100010434)
  • Hjärnfonden (ALZ2022-0006), FO2017‑0243, FO2017, ALFGBG-715986, FO2019‐0228, #ALFGBG-965240, JPND2019-466-236)
  • Vetenskapsrådet (ALFGBG-965240, ALZ2022-0006, 860197, 2017-00915, (#ALFGBG-715986, PI19/00155, 948677, ZEN-21-848495, 681712, 2018-, JPND2019-466-236, FO2017-0243, 2018-02532)
  • Vlaamse regering
  • UK Dementia Research Institute (#2017-00915, ZEN-21-848495, ALFGBG-715986, RDAPB-201809-2016615, #ALZ2022-0006, AF-968270, FO2017-0243, -965240, -968270, -939721, ALFGBG-965240, -201809-2016615, AF-930351, -715986, -930351, AF-939721)
  • Olav Thon Stiftelsen (#FO2019-0228)
  • National Institutes of Health (ID 100010434, ZEN-21- 848495, 100010434, 2018-02532)
  • Instituto de Salud Carlos III (ID 100010434, 100010434, PI19/00155)
  • National Research, Development and Innovation Office
  • National Institute on Aging (R01AG068398)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
preclinical Alzheimer's disease, amyloid-beta pathology, phosphorylated tau217, plasma biomarkers, blood biomarkers, amyloid PET, disease-modifying trials, trial participant selection, glial fibrillary acidic protein, neurofilament light chain
MeSH terms
Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-27, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease. https://app.cochat.ai/papers/10.1038/s41591-022-01925-w
The paper
Milà-Alomà, M., Ashton, N. J., Shekari, M., Salvadó, G., Ortiz-Romero, P., Montoliu-Gaya, L., Benedet, A. L., Karikari, T. K., Lantero-Rodriguez, J., Vanmechelen, E., Day, T. A., González-Escalante, A., Sánchez-Benavides, G., Minguillon, C., Fauria, K., Molinuevo, J. L., Dage, J. L., Zetterberg, H., Gispert, J. D., . . . Blennow, K. (2022). Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease. Nature Medicine. https://doi.org/10.1038/s41591-022-01925-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.